Inhibition of YAP increases cytotoxicity of chemotherapy and sensitivity to various target therapies including EGFR-TKIs, BRAF, and MEK inhibitors in NSCLC [70,71,72,73]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.